ArticleJournal of the American Heart Association2026
Development and Validation of a Machine Learning Model to Predict Oral Anticoagulant Use in Stroke From Prothrombin Time-International Normalized Ratio and Activated Partial Thromboplastin Time.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTimely recognition of oral anticoagulant use is critical in acute stroke but is often hampered by impaired consciousness and unavailable medication history. We investigated whether routinely available coagulation tests, prothrombin time-international normalized ratio and activated partial thromboplastin time, paired with machine learning can identify anticoagulant exposure at presentation.
methodsWe performed a multicenter diagnostic modeling study using the Japan Stroke Data Bank. Adults with ischemic or hemorrhagic stroke admitted in 2016 to 2021 comprised the derivation cohort; those in 2022 formed a temporally distinct validation cohort. Three models (random forest, extreme gradient boosting, and neural network) used prothrombin time-international normalized ratio and activated partial thromboplastin time as predictors to classify anticoagulant status: vitamin K antagonist, direct oral anticoagulant, or none. Discrimination (area under the receiver operating characteristic curve and area under the precision-recall curve), calibration, and decision curve analysis were assessed. Model outputs were implemented as bedside probability heat maps.
resultsAmong 30 767 patients (derivation n=24 857; validation n=5910), vitamin K antagonist/direct oral anticoagulant use was 4.5%/8.2% in derivation and 2.8%/9.5% in validation. In the validation cohort, the neural network yielded the best performance: area under the receiver operating characteristic curve, 0.933 (95% CI, 0.908-0.955) and area under the precision-recall curve, 0.52 (95% CI, 0.44-0.61) for vitamin K antagonist; area under the receiver operating characteristic curve, 0.841 (95% CI, 0.822-0.858) and area under the precision-recall curve, 0.39 (95% CI, 0.35-0.43) for direct oral anticoagulant, with preserved calibration and highest net benefit across clinically relevant thresholds. Heat maps summarized class probabilities over the prothrombin time-international normalized ratio×activated partial thromboplastin time space to support rapid inference.
conclusionsA simple machine learning model using only prothrombin time-international normalized ratio and activated partial thromboplastin time classified vitamin K antagonist and direct oral anticoagulant exposure with high accuracy and practical clinical utility. This tool assists emergency decision-making when medication history is unknown, supporting the safety and timeliness of acute stroke care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.